American Journal of Clinical Pathology · 2022 · 30 citations · 33 references
MedicineOncologyPathologyMetastasisTumor ImmunologyTumor MicroenvironmentCancer Molecular PathologyColorectal CancerEpithelial-mesenchymal TransitionImmuno-oncology BiomarkersMalignant NeoplasmsTumor Immune MicroenvironmentCd8 Positive T CellsColorectal Cancer PathologyEpithelial-mesenchymal Transition In CancerEpithelial-mesenchymal Transition MarkersMicroenvironmental AlterationsPd-l1 BlockadeProgrammed Death-ligand 1 BiomarkerTumor Microenvironment Biomarkers
OBJECTIVES: Colorectal carcinomas are the third-most common tumors in the world, and colorectal cancer ranks second in cancer-related deaths. Our aim in this study was to investigate the correlation between programmed cell death ligand 1 (PD-L1) expression and clinicopathologic parameters in colorectal carcinomas and their relationship to the tumor immune microenvironment, epithelial-mesenchymal transition (EMT), and microsatellite instability. We also investigated the predictive and prognostic role of PD-L1. METHODS: One hundred patients with a diagnosis of colorectal adenocarcinoma who did not receive neoadjuvant therapy were included in the study. The relationships among the altered expression of PD-L1; vimentin; E-cadherin; mismatch repair status; and pathologic microenvironmental features, including the presence of tumor budding and CD8-positive tumor infiltrating lymphocytes (TILs), were assessed. RESULTS: Increased PD-L1 expression in tumor cells was associated with increased TILs (P = .013), high histologic grade (P = .011), advanced pathologic T stage (P = .007), lymph node metastasis (P = .002), distant metastasis (P < .001), perineural invasion (P = .009), high bud score (P = .023), EMT (P < .001), and shorter disease-free survival (P = .029). CONCLUSIONS: Overall, PD-L1 expression in colorectal carcinoma tumor cells is a marker of poor prognosis, and the positive correlation detected between EMT status and PD-L1 expression suggests that patients with the mesenchymal phenotype may be more likely to benefit from programmed cell death 1 protein/PD-L1 immunotherapy.
33
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17